Alnylam Pharma (ALNY) Posts Q3 adj.-Loss of $0.23, Beats by 1c
More News related to ALNY
- Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
- Alnylam Pharma (ALNY) To Provide RNAi Pipeline, Platform, and Tech Update at R&D Day in NY
- Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day
- Alnylam to Webcast R&D Day on Thursday, November 12, 2009
- Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q3 adjusted loss of $0.23, 1 cent better than the analyst estimate of ($0.24). Revenue for the quarter was $24.20 million, which compares to the estimate of $26.29 million.
Related Categories
EarningsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
